0001193125-17-347756.txt : 20171220 0001193125-17-347756.hdr.sgml : 20171220 20171120121555 ACCESSION NUMBER: 0001193125-17-347756 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20171120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 10182 TELESIS COURT, 6TH FLOOR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-207-4264 MAIL ADDRESS: STREET 1: 10182 TELESIS COURT, 6TH FLOOR CITY: SAN DIEGO STATE: CA ZIP: 92121 CORRESP 1 filename1.htm CORRESP

LA JOLLA PHARMACEUTICAL COMPANY

4550 Towne Centre Court

San Diego, California 92121

November 20, 2017

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

Attention: D. Yale

Re: La Jolla Pharmaceutical Company, a California corporation (the “Company”)

Registration Statement on Form S-3

File No. 333-221198

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 PM (Eastern Daylight Time) on November 21st, 2017, or as soon thereafter as is practicable.

Very truly yours,

 

La Jolla Pharmaceutical Company

By:  

/s/ Dennis M. Mulroy

Name:  Dennis M. Mulroy
Title:  Chief Financial Officer